About Moesin
Moesin (MSN) is a protein
from Homo sapiens identified by UniProt accession
P26038, 577 residues long.
MolForge cross-references it against 0 known binders and
575 disease associations.
Target properties
| Protein name | Moesin |
| UniProt accession | P26038 |
| Gene | MSN |
| Organism | Homo sapiens |
| Length | 577 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (575)
Diseases linked to this target (Open Targets).
- combined immunodeficiency due to moesin deficiency · score 0.71
- cancer · score 0.47
- combined immunodeficiency · score 0.46
- Combined immunodeficiency · score 0.46
- liver disease · score 0.32
- anaplastic large cell lymphoma · score 0.28
- neurodegenerative disease · score 0.28
- oral squamous cell carcinoma · score 0.21
- lung adenocarcinoma · score 0.20
- neoplasm · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P26038-F1 | alphafold | PREDICTED | 86.39 | — |
Amino-acid sequence (577 residues)
MPKTISVRVT TMDAELEFAI QPNTTGKQLF DQVVKTIGLR EVWFFGLQYQ DTKGFSTWLK LNKKVTAQDV RKESPLLFKF RAKFYPEDVS EELIQDITQR LFFLQVKEGI LNDDIYCPPE TAVLLASYAV QSKYGDFNKE VHKSGYLAGD KLLPQRVLEQ HKLNKDQWEE RIQVWHEEHR GMLREDAVLE YLKIAQDLEM YGVNYFSIKN KKGSELWLGV DALGLNIYEQ NDRLTPKIGF PWSEIRNISF NDKKFVIKPI DKKAPDFVFY APRLRINKRI LALCMGNHEL YMRRRKPDTI EVQQMKAQAR EEKHQKQMER AMLENEKKKR EMAEKEKEKI EREKEELMER LKQIEEQTKK AQQELEEQTR RALELEQERK RAQSEAEKLA KERQEAEEAK EALLQASRDQ KKTQEQLALE MAELTARISQ LEMARQKKES EAVEWQQKAQ MVQEDLEKTR AELKTAMSTP HVAEPAENEQ DEQDENGAEA SADLRADAMA KDRSEEERTT EAEKNERVQK HLKALTSELA NARDESKKTA NDMIHAENMR LGRDKYKTLR QIRQGNTKQR IDEFESM
Explore Moesin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets